论文部分内容阅读
硫酸沃拉帕沙(vorapaxar sulfate,1),商品名Zontivity,化学名为硫酸N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-氟苯基)吡啶-2-基]-乙烯基]十二氢-3-甲基-1-氧代萘[2,3-c]呋喃-7-基]氨基甲酸乙酯,由默沙东公司研制开发,是一种蛋白酶激活受体1(PAR-1)拮抗剂,旨在抑制血小板的聚集,减少血凝块的形成,2014年5月获FDA批准,用于有心脏病的患者或腿部动脉有阻塞
Vorapaxar sulfate (1), trade name Zontivity, chemical name N - [(3R, 3aS, 4S, 4aR, 7R, 8aR, 9aR) -4 - [(E) -2- [5 (3-fluorophenyl) pyridin-2-yl] -vinyl] dodecahydro-3-methyl- 1 -oxo-naphtho [2,3-c] furan-7- yl] carbamate, Developed by Merck, is a protease-activated receptor 1 (PAR-1) antagonist designed to inhibit platelet aggregation and reduce blood clot formation. It was approved by the FDA in May 2014 for use in heart disease Patient or leg arteries are blocked